COVID-19 Vaccines Safety Tracking: Global Consortium Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; BBV 152 (Primary) ; Coronavirus vaccine-Wuhan Institute of Biological Products (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary) ; Elasomeran (Primary) ; NVX CoV 2373 (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary) ; Zorecimeran (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Acronyms CoVaST

05 Apr 2022 Planned End Date changed from 31 Jan 2022 to 31 Dec 2026.
05 Apr 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2025.
19 Apr 2021 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com